Literature DB >> 16912266

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.

David C Miller1, Stephen B Gruber, Brent K Hollenbeck, James E Montie, John T Wei.   

Abstract

BACKGROUND: The frequently indolent nature of early-stage prostate cancer in older men and in men with low- or moderate-grade tumors and the demonstration that the survival benefits of radical prostatectomy are primarily among men younger than 65 years have led to concerns about prostate cancer overtreatment.
METHODS: Using data from 13 Surveillance, Epidemiology, and End Results registries, we performed a retrospective cohort study of 71,602 men who were diagnosed with localized or regional prostate cancer between 2000 and 2002. We quantified the incidence of initial curative therapy (i.e., surgery or radiation therapy) among men with lower-risk cancers as defined by their limited likelihood of either dying from expectantly managed prostate cancer or achieving a survival benefit from local therapy. Stratified analyses and multinomial logistic regression models were used to quantify the absolute and relative rates of curative therapy among men in various age-grade strata. All statistical tests were two-sided.
RESULTS: We identified 24,405 men with lower-risk prostate cancers and complete data for the first course of treatment. Initial curative therapy was undertaken in 13,537 of these men (55%); 81% of treated men received radiation therapy. The likelihood of curative therapy, relative to expectant management, varied statistically significantly among lower-risk age-grade strata (all P<.05). Assuming that initial expectant management is appropriate for all lower-risk cancers, 2564 men (10%) in this population-based sample were overtreated with radical prostatectomy and 10,973 (45%) with radiation therapy.
CONCLUSIONS: These data quantify a target population for whom greater use of expectant approaches may reduce overtreatment and improve the quality of localized prostate cancer care.

Entities:  

Mesh:

Year:  2006        PMID: 16912266     DOI: 10.1093/jnci/djj308

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  78 in total

Review 1.  Management of low (favourable)-risk prostate cancer.

Authors:  H Ballentine Carter
Journal:  BJU Int       Date:  2011-12       Impact factor: 5.588

2.  Prediction of erectile function following treatment for prostate cancer.

Authors:  Mehrdad Alemozaffar; Meredith M Regan; Matthew R Cooperberg; John T Wei; Jeff M Michalski; Howard M Sandler; Larry Hembroff; Natalia Sadetsky; Christopher S Saigal; Mark S Litwin; Eric Klein; Adam S Kibel; Daniel A Hamstra; Louis L Pisters; Deborah A Kuban; Irving D Kaplan; David P Wood; Jay Ciezki; Rodney L Dunn; Peter R Carroll; Martin G Sanda
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

Review 3.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 4.  Health care reform in 2010: transforming the delivery system to improve quality of care.

Authors:  Christopher P Filson; John M Hollingsworth; Ted A Skolarus; J Quentin Clemens; Brent K Hollenbeck
Journal:  World J Urol       Date:  2010-11-03       Impact factor: 4.226

5.  Focal therapy for prostate cancer.

Authors:  Danil V Makarov; Alan W Partin
Journal:  Rev Urol       Date:  2008

6.  There is no role for focal therapy in prostate cancer.

Authors:  Peter Black
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

7.  A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Authors:  Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

8.  Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.

Authors:  Amy N Luckenbaugh; Gregory B Auffenberg; Scott R Hawken; Apoorv Dhir; Susan Linsell; Sanjeev Kaul; David C Miller
Journal:  J Urol       Date:  2016-09-20       Impact factor: 7.450

9.  The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.

Authors:  Ryan P Kopp; Lynn M Marshall; Patty Y Wang; Douglas C Bauer; Elizabeth Barrett-Connor; J Kellogg Parsons
Journal:  Eur Urol       Date:  2013-04-03       Impact factor: 20.096

10.  Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Debra J Elliot; Robert Veltri; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Bruce Trock; Lori J Sokoll
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.